Lilly to acquire Prevail Therapeutics for $1B

By The Science Advisory Board staff writers

December 15, 2020 -- Eli Lilly will acquire Prevail Therapeutics for a total consideration of up to $26.50 per share in cash, or an aggregate of approximately $1.04 billion, contingent on the first regulatory approval for commercial sale of a Prevail product in certain countries.

The acquisition will extend Lilly's research efforts through the creation of a gene therapy program anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. Currently in development are PR001 for patients with Parkinson's disease with GBA1 mutations and neuronopathic Gaucher disease, as well as PR006 for patients with frontotemporal dementia with GRN mutations.

In Prevail's preclinical pipeline are PR004 for patients with specific synucleinopathies, as well as potential gene therapies for Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurodegenerative disorders.

To receive the full $1.04 billion, regulatory approval for one of Prevail's products must be received by December 31, 2024.


Copyright © 2020 scienceboard.net
 

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:



Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Email Preferences



Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.